Recordati (Spain)

To evaluate the safety, tolerability and efficacy of a probiotic supplementation for Helicobacter pylori (H.pylori) eradication therapy. Consecutive adult naive patients with a diagnosis of H.pylori infection who were prescribed eradication therapy according to clinical practice (10-day triple or nonbismuth quadruple concomitant therapy) randomly received probiotics (1×109 colony-forming units each strain, Lactobacillus plantarum and Pediococcus acidilactici) or matching placebo. Side effects at the end of the treatment, measured through a modified De Boer Scale, were the primary outcome. Secondary outcomes were compliance with therapy and eradication rates. A total of 209 patients (33% triple therapy, 66% non-bismuth quadruple therapy) were included [placebo (n=106) or probiotic (n=103)]. No differences were observed regarding side effects at the end of the treatment between groups (β -0.023, P 0.738). Female gender (P<0.001) and quadruple therapy (P 0.007) were independent predictors of side effects. No differences in compliance were observed, regardless of the study group or eradication therapy. Eradication rates were similar between groups [placebo 95% (95% confidence interval (CI), 89% to 98%) vs probiotic 97% (95% CI, 92% to 99%), P 0.721]. There were no relevant differences in cure rates (>90% in all cases) between triple and quadruple concomitant therapy. Probiotic supplementation containing Lactobacillus Plantarum and Pediococcus acidilactici to H.pylori treatment neither decreased side effects nor improved compliance with therapy or eradication rates.

Barrios, V.1; Calderbn, A.1; Navarro, A.2; Noya, C.3; Barrios, L.1; Navarro-Cid, J.4; Tomas, J. P.1; Herranz, I.4; Prieto, L.4; Ruilopel, L. M.5 Author Information

: Tuesday, June 15, 2004: POSTER SESSIONS: Poster Session 40: Therapeutics and Clinical Pharamcology